How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

746 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Overweight and obesity - use of portion control in management

in management clinical protein in the diet, and • checking that the major carbohydrate sources in the diet have a low glycaemic index (thus supplying a source of energy over a longer period and reducing fluctuations in both blood glucose and insulin concentrations). Pharmacotherapy may assist with appetite control. A Cochrane review found that taking sibutramine resulted in weight loss 4.2 kg greater than the placebo. 34 While appetite suppressant medications may assist with weight loss, they are more

2010 Clinical Practice Guidelines Portal

162. Lack of evidence to choose second line drug treatments for type 2 diabetes

glycaemic control. This systematic review set out to find out which is the most effective choice. The reviewers conducted a search of the main bibliographic databases and found 49 randomised trials relevant to the topic. These studies evaluated the effectiveness of sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogues, insulins and insulin analogues, alpha-glucosidase inhibitors and the weight-loss agents orlistat and sibutramine. The reviewers analysed combination

2011 The Diabetes Elf

163. Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin

release), psyllium preparation such as Metamucil (>2 tablespoons/day), fibrates and derivatives, bile cholesterol absorption inhibitors including ezetimibe; Any supplement containing plan sterols/stanols (i.e. Benecol, beta‐sitosterol, Cholestatin, Phytoquest, Take Control) or cholestin (i.e. Chinese red yeast, fermented on rice; Hong Qu, Hong Chu, Herbvalin, Ruby Monascus, Monascus purpureus rice); Neomycin (oral); Adrenocortical steroids* Sibutramine (Meridia); Insulin; Orlistat (Xenical

2015 Clinical Trials

164. Health Beneficial Effects of Krill Oil and Lean and Fatty Fish

1.3-4.0 mmol/L Willingness to eat fish Willingness to not take omega-3 or other dietary supplements during the study. Exclusion Criteria: Pregnancy or lactation Any chronic disease, including diabetes type 1 or 2. CVD or cancer past 6 months Elevated thyroid hormones or TSH levels Elevated total cholesterol (>7.8 mmol/L) or fasting triglycerides (>4.0 mmol/L) Use of prescription drugs that may affect triglycerides (e.g. diabetes drugs, Cyclosporin A, Orlistat and Sibutramine), except statins

2015 Clinical Trials

165. SATIN: Satiety Innovation. Study 2- University of Aberdeen

obstruction. Psychiatric disorder: severe depression, bulimia, anorexia, schizophrenia, bipolar disorder. Gastrointestinal procedure or surgery in the past three months. Disorders of swallowing, severe dysphagia to food or pills. Pregnancy Medication exclusion criteria Appetite modulator drugs: orlistat, sibutramine, rimonabant. Mood disorder medications: antidepressants, lithium. Others: oral antidiabetics, insulin, digoxin, thyroid hormones, antibiotics, steroids or immunosuppressants, recreational

2015 Clinical Trials

166. Domperidone for Chronic Nausea and Vomiting

, norepinephrine, ondansetron, oxytocin, paliperidone, perflutren lipid microspheres, phentermine, phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ranolazine, ritodrine, roxithromycin, sibutramine, solifenacin, sunitinib, tacrolimus, telithromycin, terbutaline, terfenadine, tolterodine, trimethoprim-sulfa, vandetanib, vardenafil, voriconazole. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact

2015 Clinical Trials

167. A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

of 14 calendar days known to affect weight or glucose metabolism, such as weight loss/modifying (e.g.; sibutramine, orlistat, thyroid hormones, corticosteroids) Impaired liver function, defined as alanine aminotransferase (ALT) at least 2.5 times upper limit of normal Renal impairment eGFR (electronic case report form) below 60 mL/min/1.73 m^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Screening calcitonin at least 50 ng/L History of pancreatitis (acute or chronic) Personal

2015 Clinical Trials

168. EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects

to affect GI motility, prescription or over the counter weight loss medications such as Sibutramine hydrochloride monohydrate and Orlistat Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, and all equivalent antibiotics Any characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement in this clinical trial Previous GI surgery that could affect the ability to place the liner or the function of the implant. Subjects unable

2015 Clinical Trials

169. A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

metabolism, in excess of 14 days (i.e. sibutramine, orlistat, thyroid hormones, systemic corticosteroids and other weight loss/modifying agents) Impaired liver function, defined as ALT (alanine aminotransferase) at least 2.5 times upper limit of normal (central laboratory value measured at screening visit) Inadequately treated high blood pressure defined as Class 2 hypertension or higher (i.e. systolic blood pressure equal to or above 160 mm Hg or diastolic equal to or above 100 mm Hg) in accordance

2015 Clinical Trials

170. Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients. (PubMed)

and not medicines. Even though we did not analyze the constituents of all crude drugs, we found some active ingredients in the items. Sibutramine was detected in items confirmed to be supplements, including those containing Poria sclerotium and Ophiopogonis tuber. Each capsule contained ≈ 12 mg of sibutramine, which is the daily dose for anti-obesity medicines. Sibutramine is not approved for use in Japan and its sale has been suspended in Europe and the USA owing to serious adverse effects on the circulatory

Full Text available with Trip Pro

2015 BMC Complementary and Alternative Medicine

171. Pediatric obesity: Causes, symptoms, prevention and treatment (PubMed)

, hypothalamic melanocortin 4 receptor, and mitochondrial uncoupling proteins, are known to affect body weight. These molecules serve as potential targets for the pharmacological manipulation of obesity. Sibutramine and orlistat are primariliy used for the treatment of adult obesity, which produces modest weight loss, of 3-8% compared to placebo. For children and obese adolescents, metformin is used in the case of insulin resistance and hyperinsulinemia. Octreotide is used for hypothalamic obesity. Bariatric

Full Text available with Trip Pro

2015 Experimental and therapeutic medicine

172. Natural drugs aren’t necessary safe. Don’t make that mistake.

with anabolic steroids. Some of these contaminated supplements were Vitamin C and magnesium tablets. They also found that nutritional supplements were adulterated with the stimulants ephedrine, caffeine, methylenedioxymethamphetamine (MDMA, “ecstasy”) and sibutramine (Meridia, a prescription-only weight loss drug). This is a problem unique to the United States. In Europe, the herbal industry is as stringently regulated as the prescription medication industry. When a person purchases an herbal remedy from

2015 KevinMD blog

173. ChemDIS: a chemical–disease inference system based on chemical–protein interactions (PubMed)

. An analysis on maleic acid and sibutramine showed that ChemDIS could be a useful tool for the identification of potential functions, pathways and diseases affected by poorly characterized chemicals.ChemDIS is an integrated chemical-disease inference system for poorly characterized chemicals with potentially affected functions and pathways for experimental validation. ChemDIS server is freely accessible at http://cwtung.kmu.edu.tw/chemdis.

Full Text available with Trip Pro

2015 Journal of Cheminformatics

174. Treatment of obesity in primary care practice in the United States: a systematic review

of relevant studies and reviews were searched. Study selection Randomised controlled trials (RCTs) of weight loss interventions in adults in USA that involved counselling by a primary care provider (or in a simulated primary care setting) were eligible for inclusion. Treatments used in included studies were brief primary care provider counselling (alone or with orlistat or sibutramine) or collaborative (involved registered dietitians or nurses who supported primary care providers). Treatment duration

Full Text available with Trip Pro

2009 DARE.

175. A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

containing St. John's Wort is prohibited within 4 weeks before dosing. Treatment within 4 weeks of dosing with over-the-counter weight loss products or appetite suppressants (including herbal weight loss agents), or within 3 months of dosing with a prescription weight loss drug (eg, phentermine, sibutramine, orlistat) or lipid dissolving injections (eg, Lipodissolve). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may

2015 Clinical Trials

176. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. (PubMed)

identified through searching the Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Fourteen randomized clinical trials were included for systematic review and meta-analysis from 132 potential trials. The Comprehensive Meta-Analysis version 2 was used for meta-analysis.Difference in means and significances from meta-analyses regarding weight control by adjunctive treatments showed that topiramate, aripiprazole, or sibutramine was more effective than metformin or reboxetine. Psychiatric

Full Text available with Trip Pro

2015 TheScientificWorldJournal

177. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. (PubMed)

Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in pulse rate, and the impact (...) of these changes on subsequent cardiovascular outcome events in both the placebo and sibutramine groups.9804 males and females, aged ⩾55 years, with a body mass index of 27-45 kg m(-)(2) were included in this current subanalysis of the SCOUT trial. Subjects were required to have a history of cardiovascular disease and/or type 2 diabetes mellitus with at least one cardiovascular risk factor, to assess cardiovascular outcomes. The primary outcome event (POE) was a composite of nonfatal myocardial infarction

2015 International Journal of Obesity Controlled trial quality: uncertain

178. Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response. (PubMed)

Predicting meaningful outcomes to medication and self-help treatments for binge-eating disorder in primary care: The significance of early rapid response. We examined rapid response among obese patients with binge-eating disorder (BED) in a randomized clinical trial testing antiobesity medication and self-help cognitive-behavioral therapy (shCBT), alone and in combination, in primary-care settings.One hundred four obese patients with BED were randomly assigned to 1 of 4 treatments: sibutramine (...) , placebo, shCBT + sibutramine, or shCBT + placebo. Treatments were delivered by generalist primary-care physicians and the medications were given double-blind. Independent assessments were performed by trained and monitored doctoral research clinicians monthly throughout treatment, posttreatment (4 months), and at 6- and 12-month follow-ups (i.e., 16 months after randomization). Rapid response, defined as ≥65% reduction in binge eating by the fourth treatment week, was used to predict outcomes.Rapid

2015 Journal of Consulting and Clinical Psychology Controlled trial quality: uncertain

179. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. (PubMed)

Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. The Sibutramine Cardiovascular OUTcomes (SCOUT) trial showed a significantly increased relative risk of nonfatal cardiovascular events, but not mortality, in overweight and obese subjects receiving long-term sibutramine treatment with diet and exercise. We examined the relationship between early changes (both increases and decreases) in pulse rate, and the impact (...) of these changes on subsequent cardiovascular outcome events in both the placebo and sibutramine groups.9804 males and females, aged ⩾55 years, with a body mass index of 27-45 kg m(-)(2) were included in this current subanalysis of the SCOUT trial. Subjects were required to have a history of cardiovascular disease and/or type 2 diabetes mellitus with at least one cardiovascular risk factor, to assess cardiovascular outcomes. The primary outcome event (POE) was a composite of nonfatal myocardial infarction

2015 International Journal of Obesity Controlled trial quality: uncertain

180. Predicting Meaningful Outcomes to Medication and Self-Help Treatments for Binge-Eating Disorder in Primary Care: The Significance of Early Rapid Response. (PubMed)

Predicting Meaningful Outcomes to Medication and Self-Help Treatments for Binge-Eating Disorder in Primary Care: The Significance of Early Rapid Response. We examined rapid response among obese patients with binge-eating disorder (BED) in a randomized clinical trial testing antiobesity medication and self-help cognitive-behavioral therapy (shCBT), alone and in combination, in primary-care settings.One hundred four obese patients with BED were randomly assigned to 1 of 4 treatments: sibutramine (...) , placebo, shCBT + sibutramine, or shCBT + placebo. Treatments were delivered by generalist primary-care physicians and the medications were given double-blind. Independent assessments were performed by trained and monitored doctoral research clinicians monthly throughout treatment, posttreatment (4 months), and at 6- and 12-month follow-ups (i.e., 16 months after randomization). Rapid response, defined as ≥65% reduction in binge eating by the fourth treatment week, was used to predict outcomes.Rapid

Full Text available with Trip Pro

2015 Journal of Consulting and Clinical Psychology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>